Vivos (RDGL) Gross Margin (2010 - 2025)

Vivos (RDGL) posted Gross Margin of 12.54% for Q4 2025, up 98.16% sequentially from 682.01% in Q3 2025, and up 9326.0% YoY from 0.13% in Q4 2024.

Vivos (RDGL) Gross Margin (2010 - 2025) Analysis & Trends

Vivos has reported Gross Margin for 11 years, with the latest figure at 12.54% in Q4 2025.

Quarterly Gross Margin rose 9326.0% year-over-year to 12.54% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 87.39% (down 7673.0% YoY) and the FY2025 annual result came in at 87.39%, down 7673.0% from the prior year.
Gross Margin advanced to 12.54% in Q4 2025 per RDGL's latest filing, from 682.01% in the prior quarter.
Over five years, Gross Margin peaked at 100.0% in Q3 2023 and troughed at 682.01% in Q3 2025.
A 5-year average of 60.61% and a median of 29.47% in 2023 frame the typical range for Gross Margin.
The sharpest annual moves came in 2023 and 2025: Gross Margin soared 20054 bps in 2023, then slumped 70363 bps in 2025.
Over 5 years, Gross Margin stood at 59.7% in 2021, then sank by 209 bps to 65.04% in 2022, then surged by 254 bps to 100.0% in 2023, then tumbled by 206 bps to 105.81% in 2024, then surged by 88 bps to 12.54% in 2025.
According to Business Quant data, Gross Margin over the past three periods registered 12.54%, 682.01%, and 231.69% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Abbott Laboratories	200.19 Bn	194.59 Bn	7.27 Bn	57.71%
2	Stryker	129.95 Bn	126.47 Bn	4.50 Bn	68.27%
3	Medtronic	120.06 Bn	110.84 Bn	6.41 Bn	65.35%
4	Boston Scientific	74.14 Bn	73.60 Bn	3.85 Bn	70.71%
5	Edwards Lifesciences	52.74 Bn	48.49 Bn	1.35 Bn	77.46%
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	63.44%
7	GE HealthCare Technologies	34.20 Bn	32.10 Bn	2.18 Bn	41.17%
8	Koninklijke Philips	26.46 Bn	23.13 Bn	4.55 Bn	47.38%
9	Steris	23.25 Bn	22.77 Bn	684.20 Mn	45.84%
10	Vivos	24.90 Mn	23.34 Mn	-3,105.00	-12.54%

Download Data